

Supplementary Table S1. Clinicopathologic and molecular features of MSI-high CRCs according to tumor-infiltrating FoxP3⁺ T cell density

Variable		FoxP3-high (n = 40)	FoxP3-low (n = 86)	P-value
Tumor size	Larger (\geq 6.3 cm)	11 (27.5%)	43 (50.0%)	0.018
	Smaller (< 6.3 cm)	29 (72.5%)	43 (50.0%)	
AJCC/UICC cancer stage	Stage I/II	34 (85%)	56 (65%)	0.021
	Stage III/IV	6 (15%)	30 (35%)	
Depth of invasion (pT)	Submucosa or proper muscle (pT1/pT2)	11 (27.5%)	7 (8.1%)	0.004
	Beyond the proper muscle (pT3/pT4)	29 (72.5%)	79 (91.9%)	
Lymph node metastasis (pN)	Absent (pN0)	34 (85.0%)	59 (68.6%)	0.051
	Present (pN1/pN2)	6 (15.0%)	27 (31.4%)	
Distant metastasis (pM or cM)	Absent (M0)	40 (100%)	76 (88.4%)	0.03
	Present (M1)	0 (0%)	10 (11.6%)	
Early recurrence ^a	Absent	39 (97%)	78 (91%)	0.27
	Present	1 (3%)	8 (9%)	
Lymphatic invasion	Absent	30 (75.0%)	58 (67.4%)	0.39
	Present	10 (25.0%)	28 (32.6%)	
Venous invasion	Absent	37 (92.5%)	72 (83.7%)	0.179
	Present	3 (7.5%)	14 (16.3%)	
Perineural invasion	Absent	33 (82.5%)	62 (72.1%)	0.207
	Present	7 (17.5%)	24 (27.9%)	
Tumor grade (differentiation)	Low grade (well to moderately differentiated)	28 (70.0%)	54 (62.8%)	0.429
	High grade (poorly differentiated)	12 (30.0%)	32 (37.2%)	
CIMP	CIMP-high	15 (37.5%)	26 (30.2%)	0.418
	CIMP-low/negative	25 (62.5%)	60 (69.8%)	
<i>KRAS</i> mutation	Absent	29 (72.5%)	53 (61.6%)	0.233
	Present	11 (27.5%)	33 (38.4%)	
<i>BRAF</i> mutation ^b	Absent	35 (87.5%)	78 (92.9%)	0.331
	Present	5 (12.5%)	6 (7.1%)	

Abbreviations: MSI-high, microsatellite instability-high; CRCs, colorectal cancers; AJCC/UICC, American Joint Committee on Cancer/Union for International Cancer Control; CIMP, CpG island methylator phenotype

^aEarly recurrence was defined as clinically found and/or pathologically confirmed tumor recurrence within two years after curative surgery.

^bTwo cases were excluded in *BRAF* mutation analysis results due to suboptimal quality or quantity of their isolated DNA samples.